Brain tumor endpoints
Clinical trial endpoints for primary brain tumors will be the topic of the next public workshop in FDA's series of oncology endpoint meetings, to be held Jan. 20. "Issues identified in the workshop will be further discussed before the Oncologic Drugs Advisory Committee and thereafter will be detailed in FDA guidance documents," the agency said Nov. 22. The agency has previously hosted public meetings on lung, colorectal and prostate cancers (1"The Pink Sheet" June 28, 2004, p. 40). The workshop will be held at the Marriott in North Bethesda, Md., beginning at 8 a.m....
You may also be interested in...
FDA could consider an endpoint for prostate cancer trials that combines PSA kinetics and bone scan results, FDA Office of Cellular, Tissue & Gene Therapies Oncology Group Leader Steven Hirschfeld, MD/PhD, suggested
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.